Ninety-two eyes with newly-diagnosed chronic open angle glaucoma (COAG) were treated in a randomised prospective trial with either timolol or pilocarpine. Their visual field survival was monitored on a 3-monthly basis over 2 years using both Goldmann and Friedmann perimetry.
Comparative studies showing that competing forms of therapy can have a different influ ence in the sparing of visual fields, would provide the best means of establishing the fact that current practice does yield substan tial 'benefit'. Unfortunately the majority of studies have concentrated on intra ocular pressure effects without addressing them selves to the question of field preservation.
Only by accurate estimation of neural function can therapeutic efficacy be demonstrated conclusively. Hence, the pre sent study was carried out in order to' obtain an objective evaluation of visual field survi val, the definitive criterion of therapeutic success or failure in glaucoma management. The methods used for field evaluation were systematically derived, highly accurate and fully reproducible. The scoring systems used yielded patient data of a consistency suffi cient to provide significant field trends for a substantial proportion of the eyes under study. More extensive accounts of the scoring technique and this trial data have been pub lished elsewhere.
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Material and Methods
Patients:
A total of 50 patients, 25 in each group, were selected on a progressive, ran domised entry basis, provided they met the following criteria: (i) lOP> 21 on two occasions (2) optic disc cupping supportive of a diag nosis of glaucoma (3) visual field loss typical of nerve fibre bundle damage caused by glaucoma. Patients were excluded if they had:
(1) contra-indications as shown on the Timoptol data sheet (2) visual ability 6/9 or worse (3) retinal problems likely to affect field plotting or if it was thought they might prove to be unreliable Treatment and Dose Adjustment:
(a) Patients were followed at 3-monthly inter vals for two years. lOP and perimetry were recorded at each attendance. Field charts were quantified on the Apple computer and a linear plot drawn. If a deteriorating trend in the visual field was thought to be highly significant, the patient was withdrawn from the trial. An adverse reaction to treatment also necessitated the patient's withdrawal from the study.
Analysis:
This was directed towards (1) duration of lOP control. Figure 1 shows the distribution of initial intraocular pressures and Friedmann scores for patients in both treatment groups. It can be seen that no correlation exists between intraocular pressures and initial field scores; indeed, the worst visual function was found in those with lower intraocular pressure levels at presentation. It is also noteworthy that those individuals with high pressures and minimal field deficit were not "ocular hyper tensives", but had indeed presented with fun dal characteristics consistent with a clinical diagnosis of COAG. The truncation of this distribution of pressures below 20 mm. Hg.
should not be construed to represent a true physiological cut-off point, but is merely a manifestation of the entry requirements for the study. Certainly it would appear highly probable that assessment of referrals with lower pressures would yield many further cases of significant visual field deficit.
Friedmann Field Responses over 18 months
Comparative assessment of the progress of patients on the two drugs was performed by considering the mean Friedmann field score change from the mean in initial field score value for each patient group, at three monthly intervals. The analysis suggests an association between a transient period of Friedmann field score improvement and timolol therapy (Fig. 2) . This effect appeared to develop dur ing the first three months of therapy, and was sustained in the timolol-treated population over the first year of treatment.
The Pilocarpine-treated group, however, showed an immediate and sustained linear downward progression in Friedmann field scores.
A breakdown of the individual figures for field scores after the initial recovery phase shows that progressive field loss occurred later in 24% of timolol-treated eyes.
Fifty-nine per cent showed no significant rate of change, and three eyes on timolol (9%) showed ongoing trends of significant central field improvement.
Comparative assessment of the progress of patients on the two drugs was performed by considering the mean Goldmann score change between the first visit and those obtained at subsequent visits within three monthly intervals, beginning at 4 months. There was no significant difference in the 3-monthly field survival responses of the two patient groups at isopter 12e on the basis of this analysis.
The overall difference between the field survival scores of the two patient groups at isopter 14e also failed to reach a conventional level of significance. A consideration of lOP reduction in these groups in terms of mean percentages of pressure reduction yields no useful correlation with field survival response. Some eyes showing severe deterio ration had actually undergone a significantly greater degree of lOP reduction than those exhibiting progressive field improvement! There were no effective therapeutic differ ences between these two groups. All 34 eyes showing significant field trends, positive or negative, responded to therapy with reduc tion in their mean lOP values. 
Relationship of Initial Field Score to Sub sequent Field Survival Trend:
One widely asserted opinion is that patients presenting with a more severe degree of field loss initially will tend to progress more rapidly than those detected at an earlier stage. There was clearly no significant corre lation between these two variables in the patient population tested. Figure 3 shows a relationship between post-treatment lOP and field score gradients as calculated from 12e Goldmann perimetric traces.
Discussion
Large scale epidemiological studies in the United States of America and elsewhere have repeatedly shown a low association between raised lOP and glaucomatous visual field loss.6.7 An interpretation of the results of these studies suggests that an examination of all individuals with mean lOPs over 21 mm. Hg. would result in a failure to detect over 60% of glaucomatous defects; that is, (Fig.  4) . Neither was there any correlation, in our series, between initial lOP presentation and the severity of central field loss. One also finds that in analysis of the prog ress of glaucoma under various forms of therapy no useful correlation has been estab lished between the measured lOP reductions achieved by medical or surgical therapy and any ensuing visual field change.8-13 All of the usual forms of therapy provided sustained reductions in the lOP of patients who had previously had abnormally high pressures. In each case correlation between the extent of lOP reduction and field survival was minimal or absent. Some forms of therapy may be better than others in terms of field survival. These facts justify a search for therapeutic agents whose beneficial effects may be entirely lOP-independent.
The weight of evidence against there being a direct cause-and-effect relationship between intraocular hypertension and COAG is strong. In the KCH data study the figures show that if all eyes with ocular hypertension were treated successfully and removed from the data, the vast majority of those with glaucomatous field loss would remain, 14 Although excessively high, lOP itself may not be the primary cause of COAG. A dis turbed aqueous circulation might nevertheless remain a likely influence in the cause of glaucoma field loss, and most present treat ments are designed to restore or modulate the aqueous circulation. Clearly, however, simple measurement of lOP in a clinical set ting has very limited value in detecting or monitoring eyes with COAG as so many fac tors influence the intraocular pressure.
Even after trabeculectomy (or other drain age procedure) there is a poor correlation between lOP reduction and field survival.!3
If one is looking for other causes of nerve destruction in COAG attention should be paid to the optic nerve where vascular insuffi ciency is important. Our observation of an lOP-independent restorative field effect of timolol may be related to the drug's ability to selectively enhance choroidal and retinal cir culation.l5, 16 In the process of disc cupping there is loss of glial tissue as well as nerve fibres, and a chronic ischaemic basis for cup ping seems more plausible than direct hydro static pressure. The glial/neural shrinkage may exacerbate vascular insufficiency and/or inhibit axoplasmic transport from ganglion cells to the lateral geniculate bodies.
Refinements in perimetry are important and we believe that improved methods of data analysis are even more so.
Conclusion
In the study the perimetric reproducibility was very high, and the transcription of field charts into computer memory precise.
The findings reported here fully corrobo rate those reported in our earlier retrospec tive study which conduded that field survival provides a far more consistent guide to the progress of glaucoma under treatment than does lOP (p« O. OOl). The apparent lack of any useful correlation between lOP and vis ual field survival in many eyes was clearly noted at that time. 3 The results of this trial suggest that, within the observed lOP limits, intraocular pressure measurements provide less useful informa tion to the clinician concerning the visual fate of the patients once they have commenced treatment with pilocarpine or timolol.
The most immediately striking finding in terms of field response to treatment is the sig nificant differences observed between the timolol and pilocarpine groups as compared by Friedmann central field analysis. Improve ment in Friedmann scores developed over the course of the first three months. The basis for this marginal improvement in the timolol group is uncertain.
Conversely, the pilocarpine-treated eyes showed an immediate and sustained down ward progression of central field function and the functional level in the timolol-treated patients is superior to that in the pilocarpine treated group at every stage examined. Timolol seems to 'buy time' in addition to giving the transient improvement in some eyes.
The pressure lowering effects of the two drugs in this trial were virtually identical, but one drug appears to have significantly improved central field function, while the other has given negative field response.
